Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
14.05
+0.26 (1.89%)
At close: Mar 19, 2026, 4:00 PM EDT
14.05
0.00 (0.00%)
After-hours: Mar 19, 2026, 5:01 PM EDT
Amylyx Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
1.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 87.37M | -293.42M | -77.06% |
| Dec 31, 2023 | 380.79M | 358.56M | 1,612.94% |
| Dec 31, 2022 | 22.23M | 21.95M | 7,700.00% |
| Dec 31, 2021 | 285.00K | -365.00K | -56.15% |
| Dec 31, 2020 | 650.00K | -776.00K | -54.42% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Perrigo Company | 4.25B |
| Phibro Animal Health | 1.46B |
| ANI Pharmaceuticals | 883.37M |
| BioCryst Pharmaceuticals | 874.84M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Alvotech | 573.35M |
AMLX News
- 14 days ago - Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point - Seeking Alpha
- 16 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 21 days ago - Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
- 23 days ago - Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 - Business Wire
- 6 weeks ago - HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 2 months ago - Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S - Business Wire
- 3 months ago - Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire